Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Influenza Vaccine Provides Protection Despite Drifted Strains, CDC Says

This article was originally published in The Pink Sheet Daily

Executive Summary

An adult case-control study found that influenza vaccine may still provide "substantial health benefit" despite a suboptimal match between circulating and vaccine strains. The Centers for Disease Control & Prevention is planning to conduct two pediatric prospective flu vaccine studies for the 2004-2005 season.

You may also be interested in...



Influenza B Virus Strain For 2004-2005 To Be Confirmed In March

FDA committee recommends switch from a Victoria to a Yamagata lineage influenza B strain. For influenza A, New Caledonia (H1N1) strain will be retained, while a Fujian-like strain will replace this season's Panama-like strain.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel